Robotic-Assisted Sleeve Lobectomy for Stage IIB-III Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy

What this Trial Is About

Researchers are studying patients with stage IIB-III non-small cell lung cancer NSCLC who undergo robotic-assisted sleeve lobectomy after receiving neoadjuvant chemoimmunotherapy. This observational study aims to understand the rate of unsuccessful surgeries and the factors that contribute to surgical difficulty. It also explores surgeons subjective assessments of challenges during these operations to improve understanding of technical issues and outcomes. Participants first receive neoadjuvant chemoimmunotherapy, which includes PD-1PD-L1 inhibitors combined with platinum-based chemotherapy, sometimes with additional thoracic radiotherapy. After this treatment, patients undergo robot-assisted thoracoscopic surgery RATS sleeve lobectomy with systematic lymph node removal. The study collects clinical, surgical, pathological, and short-term postoperative data, focusing on surgery success and difficulty. During the study, surgeons will evaluate intraoperative challenges such as pleural adhesions, fibrosis, lymph node fusion, and vascular inflammation. Researchers will monitor surgical success up to four weeks post-surgery and assess hospital stay length up to 30 days. Participants will undergo imaging before and after treatment, and their follow-up continues for 30 days to track outcomes and complications.

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC